

**PTA - EXPRESS MAIL ONLY**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb,  
David M. Knight and Scott Siegel

Divisional Application of

Application No.: 09/133,119

Filed: August 12, 1998

For: ANTI-TNF ANTIBODIES AND PEPTIDES OF HUMAN  
TUMOR NECROSIS FACTOR

Date: 01-08-01

EXPRESS MAIL LABEL NO. EL551 547 474 45

**REMARKS**

Box PATENT APPLICATION

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The above-captioned application is a divisional of application number 09/133,119, filed on August 12, 1998 to which priority is claimed under 35 U.S.C. §120.

The Specification has been revised to incorporate amendments filed in the parent application and to correct minor typographical errors and informalities. The Related Applications paragraph has been revised and updated to include the parent application and issued patents. The discussion of WEHI cytotoxicity assays of fusion proteins has been moved from Example XXVI to Example XXVII for clarity.

Three incomplete sentences in the Specification have been completed for clarity. The first two sentences of the description of Figures 31A-31C have been amended to read: "Figures 31A-31C are graphical representations showing that fusion proteins protected WEHI 164 cells from TNF $\alpha$  cytotoxicity. Cells were first sensitized to TNF $\alpha$  with actinomycin D and then



incubated in 2 ng/ml TNF $\alpha$  with varying concentrations of TNF $\alpha$  overnight at 37°C.” See page 15, lines 12-15. The sentence in Example XXVI bridging page 145, line 29 - page 146, line 2, has been amended to read: “pH 730 contains coding sequences for all three constant domains of human IgG1 and was designed to accomodate the Xba1 fragments of pH707 at a unique Xba1 site upstream of the IgG1 coding sequences (Figure 28).” Support for these amendments is found in application 08/010,406 (the ‘406 application), filed January 29, 1993, which is entirely incorporated into the present Specification by reference (see page 1, lines 4-18 of the present Specification). Specifically, support for the amendment on page 15, lines 12-15 of the present Specification is found in the ‘406 application on page 8, lines 19-26, and the accompanying ‘406 Figures 5A-C. Support for the amendment on page 145, line 29 - page 146, line 2 of the present Specification is found on page 21, lines 31-34 of the ‘406 application.

The “Sequence Listing” (sheets 1/6 through 6/6) has been inserted.

Figures 16A-16B and Figures 32A-32B have been deleted and Figures 17A-31 and Figures 33A-36 have been renumbered accordingly. Formal drawings are being filed in lieu of the informal drawings originally filed with the parent application. Please note that this deletion and renumbering of the figures took place in the parent application (09/133,119), and it is being done in the instant application to be consistent. Formal Figure 32 has been revised to correct a typographical error in the figure legend.

Claims 1-34 have been omitted and new Claims 1-55 have been added.

If the Examiner desires, Applicants will produce a redlined version or other comparison document comparing this application with the immediate parent thereof. No new matter has been added. As such, a copy of the declaration from the parent application is being filed herewith.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Deirdre E. Sanders

Deirdre E. Sanders

Registration No. 42,122

Telephone (781) 861-6240

Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *January 8, 2001*